How Xofigo Works for Prostate Cancer

Xofigo (radium Ra 223 dichloride) is a radioactive drug used to treat men with prostate cancer that has spread to the bones (metastatic bone cancer). It is a type of targeted therapy that works by delivering radiation directly to cancer cells.

Xofigo is made up of a radioactive isotope of radium, which is called radium-223. Radium-223 is a very weak beta emitter, which means that it emits low-energy radiation that can only travel a short distance. This allows Xofigo to deliver radiation directly to cancer cells in the bones without damaging nearby healthy tissue.

When Xofigo is injected into the bloodstream, it travels to the bones and is absorbed by cancer cells. The radiation emitted by Xofigo then damages the DNA of cancer cells, causing them to die.

Xofigo is typically given once a month for 6 months. It is usually given in combination with other treatments for prostate cancer, such as chemotherapy or hormone therapy.

Xofigo can cause side effects, such as nausea, vomiting, fatigue, constipation, and bone pain. These side effects are usually mild and go away after a few weeks.

How effective is Xofigo?

Xofigo has been shown to be effective in treating prostate cancer that has spread to the bones. In clinical trials, Xofigo was shown to reduce the risk of death by 30% in men with metastatic prostate cancer. Xofigo also helped to improve bone pain and other symptoms of prostate cancer.

Who is a good candidate for Xofigo?

Xofigo is a good candidate for men with prostate cancer that has spread to the bones. It is typically used in men who have failed other treatments for prostate cancer, such as chemotherapy or hormone therapy.

How is Xofigo given?

Xofigo is given as an injection into a vein (IV). It is typically given once a month for 6 months.

What are the side effects of Xofigo?

Xofigo can cause side effects, such as nausea, vomiting, fatigue, constipation, and bone pain. These side effects are usually mild and go away after a few weeks.

Is Xofigo safe?

Xofigo is a safe and effective treatment for prostate cancer that has spread to the bones. It has been studied in clinical trials and has been shown to be effective in reducing the risk of death and improving symptoms.